The Relationship Between Atrial Fibrillation and Frailty in Community-Dwelling Elderly

The Relationship Between Atrial Fibrillation and Frailty in Community-Dwelling

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03420326

Enrollment

256

Registered

2018-02-05

Start date

2018-01-26

Completion date

2018-06-01

Last updated

2019-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Frail Elderly Syndrome

Keywords

Atrial Fibrillation, Frailty status, Body composition, Sarcopenia

Brief summary

Atrial fibrillation (AF) is the most common arrhythmias in clinical practice. Research investigating hospitalized patients have indicated there are deleterious effects of AF on patients besides the disease burden itself, including longer stay days for hospitalization, higher rates of frailty and increasing mortality rate after discharged in six months. In the community-dwelling research also found that elderly with AF have lower cognitive function, physical functional tests score and slower walking speed compared with the health ones. However, there is limited articles investigating the impact of AF on community-dwelling elderly, and the relationship between AF and frailty is also lack of discussion. According to the aged society and increasing prevalence of AF, the relationship between AF and frailty in community-dwelling elderly is warranting investigated.

Interventions

BEHAVIORALFrailty status assessment

The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Older than 65 years old

Exclusion criteria

diagnosed with the following disease 1. Cardiovascular diseases: myocardial infarction, peripheral vascular diseases, aortic plaque 2. Cerebrovascular disease: stroke, transient ischemic attack, emboli 3. Heart failure 4. Participants who cannot finish the trial

Design outcomes

Primary

Measure	Time frame	Description
Frailty status	The frail status assessment would take about 10 minutes	Edmonton frail scale and Frailty criteria by Dr. Fried would be used to evaluate the frail status of the participants

Secondary

Measure	Time frame	Description
Body composition	The body composition test would take about 10 minutes	Maltron BioScan BF-920, Essex, UK would be used to assess participants' body composition

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026